Antengene Corp Ltd

Detailed Description

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-010 (selinexor), a SINE compound targeting XPO1, a key nuclear export protein for the treatment of hematologic malignancies, such as multiple myeloma and DLBCL. The company's products in pipeline include ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of various advanced solid tumors and hematological malignancies; ATG-016 (eltanexor), a SINE compound; ATG-527 (verdinexor), which is in Phase I clinical trial primarily for oncology; ATG-019, an oral dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; and ATG-017, an oral selective ERK1/2 inhibitor for the treatment of various solid tumors and hematological malignancies. Its products in pre-clinical stage include ATG-101, a PD-L1/CD137 (4-1BB) bi-specific antibody for the treatment of hematological malignancies and solid tumors; ATG-018, a small molecule inhibitor targeting ataxia telangiectasia and Rad3 related (ATR) kinase for the treatment of hematological malignancies and solid tumors; ATG-022, a humanized IgG1 monoclonal antibody against human Claudin 18.2 (CLDN18.2) antigen for the treatment of solid tumors; and ATG-012, a KRAS G12C inhibitor against KRAS oncoprotein for the treatment of solid tumors. The company was founded in 2016 and is headquartered in Shanghai, China.